Jaguar Health to Initiate Commercial Footprint in Cancer Supportive Care

 Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force

Top line results imminent for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea

18 million people in U.S. are living with a cancer diagnosis and more than 2 million people in U.S. are expected to be diagnosed with cancer in 2024

https://www.accesswire.com/866208/jaguar-health-to-initiate-commercial-footprint-in-cancer-supportive-care-at-american-society-of-clinical-oncology-asco-annual-meeting-with-exhibit-booth-for-fda-approved-gelclair-oral-mucositis-product